<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146078</url>
  </required_header>
  <id_info>
    <org_study_id>RUSH2A</org_study_id>
    <nct_id>NCT03146078</nct_id>
  </id_info>
  <brief_title>Rate of Progression in USH2A Related Retinal Degeneration</brief_title>
  <acronym>RUSH2A</acronym>
  <official_title>Rate of Progression in USH2A Related Retinal Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Fighting Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project funded by the Foundation Fighting Blindness is to
      characterize the natural history of disease progression in patients with USH2A related
      retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or
      non-syndromic retinitis pigmentosa (RP39).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This natural history study of patients with USH2A mutations will accelerate the development
      of outcome measures for clinical trials. Sensitive, objective outcome measures of retinal
      degeneration will greatly facilitate development of treatments for Usher syndrome patients.
      Together these approaches are expected to have an impact on understanding USH2A-related
      retinal degeneration, developing experimental treatment protocols, and assessing their
      effectiveness.

      The goals and expected impact of this natural history study are to:

        1. Report the natural history of retinal degeneration in patients with biallelic mutations
           in the USH2A gene

        2. Identify sensitive structural and functional outcome measures to use for future
           multicenter clinical trials in USH2A-related retinal degeneration

        3. Identify well-defined subpopulations for future clinical trials of investigative
           treatments for USH2A-related retinal degeneration

      Study Objectives

      The primary objectives of the natural history study are to:

        1. Characterize the natural history of retinal degeneration associated with biallelic
           pathogenic mutations in the USH2A gene over 4 years, as measured using functional
           outcome measures (static perimetry, microperimetry, full-field stimulus threshold (FST),
           electroretinography (ERG), and visual acuity)

        2. Characterize the natural history of retinal degeneration associated with biallelic
           pathogenic mutations in the USH2A gene over 4 years, as measured using structural
           outcome measures (spectral-domain optical coherence tomography (SD-OCT) ellipsoid zone
           (EZ) area)

        3. Investigate structure-function relationships for insights into the mechanisms of retinal
           degeneration by relating changes in SD-OCT EZ area to visual field progression in
           individuals with biallelic pathogenic mutations in the USH2A gene

        4. Assess for possible genotype, phenotype, and environmental risk factors with progression
           of the outcome measures at 4 years in individuals with biallelic pathogenic mutations in
           the USH2A gene

      Some additional secondary objectives of this study include:

        1. Characterize baseline cross-sectional retinal degeneration associated with biallelic
           pathogenic mutations in the USH2A gene (as measured using the main outcome measures)

        2. Investigate comorbidities associated with disease (baseline cross-sectional) and disease
           progression (longitudinal natural history study) in individuals with biallelic
           pathogenic mutations in the USH2A gene

        3. Explore patient reported outcome (PRO) measures associated with disease (baseline
           cross-sectional) and disease progression (longitudinal natural history study) in
           individuals with biallelic pathogenic mutations in the USH2A gene

        4. Evaluate variability and symmetry of left and right eye kinetic perimetry and SD-OCT
           outcomes at baseline and at 4 years in individuals with biallelic pathogenic mutations
           in the USH2A gene
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Field Sensitivity</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Measured by static perimetry with topographic analysis (Hill of Vision)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Best corrected E-ETDRS visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Retinal Sensitivity</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Measured by fundus-guided microperimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EZ area</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Measured by SD-OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rod- and cone-mediated retinal function</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Measured by FST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Retinal function</measure>
    <time_frame>Baseline and after four years</time_frame>
    <description>Full-field ERG amplitudes and timing in response to rod- and cone-specific stimuli</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Usher Syndrome, Type 2A</condition>
  <condition>Retinitis Pigmentosa 39</condition>
  <arm_group>
    <arm_group_label>Primary Cohort</arm_group_label>
    <description>Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (&quot;primary cohort&quot;) will be enrolled into the longitudinal natural history study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary Cohort</arm_group_label>
    <description>Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (&quot;secondary cohort&quot;) will be enrolled in the cross-sectional baseline study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential eligibility will be assessed during a routine examination by an investigator
        prior to obtaining informed consent, as part of usual care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to complete the informed consent process

          -  Ability to return for all study visits over 48 months if in the natural history study

          -  Age ≥ 8 years

          -  At least 2 pathogenic or likely pathogenic mutations in USH2A gene from a clinically
             certified lab report

        Ocular Inclusion Criteria

        Both eyes must meet all of the following:

          -  Clinical diagnosis of a rod-cone degeneration

          -  Clear ocular media and adequate pupil dilation to permit good quality photographic
             imaging

          -  Ability to perform kinetic and static perimetry reliably

        Exclusion Criteria:

          -  Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of
             biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A

          -  Expected to enter experimental treatment trial at any time during this study

          -  History of more than 1 year of cumulative treatment, at any time, with an agent
             associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine,
             thioridazine, and deferoxamine)

        Ocular Exclusion Criteria

        If either eye has any of the following, the patient is not eligible:

          -  Current vitreous hemorrhage

          -  Current or any history of rhegmatogenous retinal detachment

          -  Current or any history of (e.g., prior to cataract or refractive surgery) spherical
             equivalent of the refractive error worse than -8 Diopters of myopia

          -  History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating
             keratoplasty, or LASIK) within the last 3 months

          -  Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucoma
             visual field, nerve changes, or glaucoma filtering surgery)

          -  Current or any history of retinal vascular occlusion or proliferative diabetic
             retinopathy

          -  Expected to have cataract removal surgery during the study

          -  History or current evidence of ocular disease that, in the opinion of the
             investigator, may confound assessment of visual function

          -  History of treatment for retinitis pigmentosa that could affect the progression of
             retinal degeneration (including participation in a clinical trial within the last year
             or a retained drug delivery device)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacque Duncan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Coordinating Center</last_name>
    <phone>813 975 8690</phone>
    <email>ffb@jaeb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacque Duncan, MD</last_name>
      <email>jacque.duncan@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Kay, MD</last_name>
      <email>christinenkay@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nieraj Jain, MD</last_name>
      <email>nieraj.jain@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-9277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandeep Singh, M.D.</last_name>
      <email>msingh27@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Eye Institute/National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-2510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wadih Zein, MD</last_name>
      <email>zeinw@nei.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Huckfeldt, MD</last_name>
      <email>rachel_huckfeldt@meei.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiran K Jayasundera, MD</last_name>
      <email>thiran@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Zarbin, MD</last_name>
      <email>zarbin@earthlink.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Reimann, MSPH</last_name>
      <email>mailto:jr3538@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Iannaccone, MD</last_name>
      <email>alessandro.iannaccone@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSHU Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Pennesi, MD, PhD</last_name>
      <email>pennesim@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Pennesi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brich, PhD</last_name>
      <email>dbirch@retinafoundation.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Eye Physicians and Surgeons</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J Stout, MD, PhD, MBA</last_name>
      <email>jtstout@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Bernstein, MD, PhD</last_name>
      <email>paul.bernstein@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wiconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Conner, MD</last_name>
      <email>tconnor@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bart Leroy, MD</last_name>
      <email>bart.leroy@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elise Heon, MD</last_name>
      <email>elise.heon@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de la Vision</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Alain-Sahel, MD</last_name>
      <email>j.sahel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tubingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Stingl, MD</last_name>
      <email>Katarina.Stingl@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carel Hoyng, MD</last_name>
      <email>Carel.Hoyng@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hostpital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Michaelides, MD</last_name>
      <email>michel.michaelides@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ffb.jaeb.org</url>
    <description>public website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Usher Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified database is placed in the public domain on the FFB/Jaeb public website after the completion of each protocol and publication of the primary manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

